




RealRate

HEALTH SERVICES 2026

Viridian Therapeutics Inc DE Rank 18 of 58





RealRate

HEALTH SERVICES 2026

Viridian Therapeutics Inc DE Rank 18 of 58



The relative strengths and weaknesses of Viridian Therapeutics Inc DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viridian Therapeutics Inc DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 121% points. The greatest weakness of Viridian Therapeutics Inc DE is the variable Other Revenues, reducing the Economic Capital Ratio by 33% points.

The company's Economic Capital Ratio, given in the ranking table, is 192%, being 42% points above the market average of 150%.

Input Variable	Value in 1000 USD
Assets, Current	894,233
Assets, Non-Current	3,957
Cost of Goods and Services Sold	0
Depreciation, Depletion, Amortization	0
General and Administrative Expense	95,315
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	70,696
Long Term Liabilities	2,341
Operating Costs and Expenses	0
Other Assets	0
Other Compr. Net Income	457
Other Expenses	338,929
Other Liabilities	104,214
Other Net Income	20,794
Other Revenues	70,849
Property Plant and Equipment	1,228
Research And Development Expense	0
Selling and Marketing Expense	0

Output Variable	Value in 1000 USD
Assets	899,418
Liabilities	177,251
Expenses	434,244
Revenues	70,849
Stockholders Equity	722,167
Net Income	-342,601
Comprehensive Net Income	-342,144
BaseVar	801,506
ECR before LimitedLiability	131%
Economic Capital Ratio	192%